MyoKardia, Inc. (NASDAQ:MYOK) issued its earnings results on Thursday. The biotechnology company reported ($0.42) EPS for the quarter, meeting the consensus estimate of ($0.42), Bloomberg Earnings reports. The company had revenue of $5.63 million during the quarter, compared to analysts’ expectations of $6.10 million. MyoKardia had a negative net margin of 53.49% and a negative return on equity of 18.01%. The business’s revenue for the quarter was up 58.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.35) EPS.

Shares of MyoKardia (NASDAQ MYOK) traded up $3.20 during trading on Friday, hitting $42.20. 758,392 shares of the company traded hands, compared to its average volume of 342,821.

COPYRIGHT VIOLATION NOTICE: “MyoKardia, Inc. (MYOK) Posts Quarterly Earnings Results, Meets Estimates” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/03/myokardia-inc-myok-posts-quarterly-earnings-results-meets-estimates.html.

In related news, insider Joseph Lambing sold 5,000 shares of MyoKardia stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $45.00, for a total value of $225,000.00. Following the completion of the transaction, the insider now directly owns 99,718 shares in the company, valued at $4,487,310. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Anastasios Gianakakos sold 4,300 shares of MyoKardia stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $40.86, for a total value of $175,698.00. The disclosure for this sale can be found here. Insiders sold 1,749,213 shares of company stock valued at $73,805,529 over the last quarter. Insiders own 33.40% of the company’s stock.

MYOK has been the subject of several analyst reports. Credit Suisse Group restated an “outperform” rating and issued a $55.00 target price (up from $45.00) on shares of MyoKardia in a research report on Tuesday, September 19th. Zacks Investment Research cut shares of MyoKardia from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. ValuEngine upgraded shares of MyoKardia from a “sell” rating to a “hold” rating in a research report on Monday, August 7th. Wedbush restated an “outperform” rating and issued a $51.00 target price on shares of MyoKardia in a research report on Wednesday, September 20th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $65.00 price target (up from $45.00) on shares of MyoKardia in a report on Monday, August 21st. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $55.00.

MyoKardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Earnings History for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.